Peter Attia· MD
so we have a study 78 million dollars that was our initially budget and now we have three pockets because we had three specific aim the primary outcome is the fda outcome it's prevention of edge-related disease and mortality okay this is about 35 million dollars and this is the afr grant the second part is biomarkers we want to make sure that we know what are the biomarkers for metformin action and for aging and this was funded by the nia and will get the money once the tame is funded in order to take plasma and blood and dna and everything and be able to do omics and other things and find biomarkers the third part could come later and this is the geriatric part you know how many hospitalization and what's the adl and the frailty index and and things like that we have enough power to do it at the end of looking at people at the end and people with metformin and without metformin but of course it will be better to start at baseline but we're not funded for that yet